Researchers at Albert Einstein College of Medicine, Boston University and Tufts pooled three independent longitudinal cohorts (LonGenity, the New England Centenarian Study, and the UK Biobank) totalling 4,030 participants to ask a simple question: do the children of people who reached 100 actually age more slowly, or do they just come from families that report good health? Using survival modelling with age as the timescale, they found that centenarians’ offspring had roughly a 42 percent lower hazard of death, a 33 percent lower hazard of cardiovascular disease and a 32 percent lower hazard of hypertension than matched controls whose parents died before 85. Translated into time, that is about 3.1 extra years before death and about 5.2 extra years before a hypertension diagnosis. Cancer showed no protection at all in any cohort. The protection survived adjustment for smoking, socioeconomic status, alcohol, exercise and diet, which is the finding that matters most.
The idea that longevity runs in families is old. What has been missing is evidence that holds up when you run the same analysis, the same way, in three populations that share almost nothing except a research question. This study does that.
The three cohorts are deliberately mismatched in useful ways. LonGenity recruited Ashkenazi Jewish participants around New York City. The New England Centenarian Study recruited across the United States. The UK Biobank recruited half a million middle-aged Britons and knows nothing about centenarian families as such, so the researchers reconstructed the comparison from parental age at death recorded at enrolment. Different countries, different recruitment logic, different ways of capturing disease events, one consistent answer.
Across all three, having at least one parent who reached 100 was associated with a lower risk of dying and a lower risk of developing cardiovascular disease and high blood pressure at any given age. The hazard ratios cluster tightly: 0.58 for death, 0.67 for cardiovascular disease, 0.68 for hypertension. Stroke risk was sharply lower in the two American cohorts but not in the UK Biobank.
The more interesting result is what did not move. Cancer risk was flat, with a pooled hazard ratio of 0.88 and confidence intervals that comfortably include no effect. Whatever these families inherit, it protects arteries and blood pressure regulation and does not appear to protect against tumour formation. The authors suggest the offspring may survive cancer better rather than avoid it, though the study cannot test that.
The second thing that did not move was the effect after lifestyle adjustment. Smoking, education, income, alcohol, exercise and diet were all fed into the models. The protection barely budged. Prior work in LonGenity found the same pattern, with centenarians’ offspring protected from cardiovascular disease despite obesity, smoking and physical activity rates similar to controls.
That is the big idea, and it cuts both ways. For the biology, it means these families carry something worth isolating, which is the entire argument for using them as a discovery population for drug targets. For the individual, it is a reminder that the effect being studied here is inheritance, not behaviour. Nothing in this paper tells you how to acquire it.
Insights
It is an observational cohort study of inherited advantage, so the take-home messages are about risk stratification rather than supplementation.
Parental lifespan is a usable, free risk marker. If one of your parents reached 100, the data suggest your hazard of developing hypertension at any given age is about a third lower than someone whose parents died before 85. In the best-matched comparison (UK Biobank, participants matched one to one on age, sex and education), 47 percent of controls developed hypertension versus 36 percent of centenarians’ offspring. That is an 11 percentage point absolute difference. Roughly nine people would need to have a centenarian parent for one fewer case of hypertension to appear.
For cardiovascular disease the same comparison gives 16 percent versus 10 percent, a 6 percentage point difference. For death during follow-up, 14 percent versus 9 percent.
In effect-size terms these are small by the usual convention. Converting the hazard ratios to Cohen’s d gives about 0.30 for death, 0.22 for cardiovascular disease and 0.21 for hypertension. Small effects sustained across an entire lifetime still produce years of difference, and that is the correct way to read them.
The practical inversion matters more. If your parents died young of cardiovascular causes, you sit in the control arm of this study, and blood pressure and lipid management deserve earlier and more aggressive attention than population guidelines suggest. Cancer screening should not be relaxed for anyone based on family longevity, since this study found zero protection there.
Context and Source
- Open Access Paper: Exceptional Parental Longevity and Onset of Morbidity and Mortality Across Cohorts
- Lead institution: Institute for Aging Research, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York. Co-authoring institutions include Boston University Chobanian and Avedisian School of Medicine, Tufts Medical Center and Tufts University School of Medicine.
- Country: United States (cohort data from the United States and the United Kingdom)
- Journal: JAMA Network Open, 2026
-
Conflicts worth noting: one author holds a patent application on pegylated growth hormone receptor antagonists for Alzheimer disease and aging; one author reports personal fees from the XPRIZE Foundation; one author’s spouse holds pharmaceutical stock. None of these bear directly on the analysis.
Journal impact: The impact score of this journal is 9.7, evaluated against a typical high-end range of 0 to 60 plus for top general science and medicine, therefore this is a Medium-to-High impact journal.